The MiningNewsWire Podcast

The early days of ecommerce can be traced back decades, sluggish until the 2000s, then accelerating rapidly over the last 10-plus years. Online gaming is on a similar trajectory. Analogous to what Amazon and Alibaba did for ecommerce, online gaming has deep roots that go back decades and now has entered a growth stage that many believe will chart like a hockey stick. There are different approaches to capitalizing on what appears to be parabolic growth across the industry. More merchants than miners became millionaires during the California gold rush, and servicing the companies that provide consumer gaming just might be one of the best ways to cash a ticket. Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (Profile), a Software-as-a-Service (“SaaS”) technology company, is laser focused on that business-to-business (“B2B”) market, developing and licensing unique digital content for the iGaming market. Other companies jockeying for the end user, curating gaming and gambling services for consumers (“B2C”) include Bally’s Corporation (NYSE: BALY), DraftKings Inc. (NASDAQ: DKNG), Golden Nugget Online Gaming Inc. (NASDAQ: GNOG) and Penn National Gaming Inc. (NASDAQ: PENN).

The early days of ecommerce can be traced back decades, sluggish until the 2000s, then accelerating rapidly over the last 10-plus years. Online gaming is on a similar trajectory. Analogous to what Amazon and Alibaba did for ecommerce, online gaming has deep roots that go back decades and now has entered a growth stage that many believe will chart like a hockey stick. There are different approaches to capitalizing on what appears to be parabolic growth across the industry. More merchants than miners became millionaires during the California gold rush, and servicing the companies that provide consumer gaming just might be one of the best ways to cash a ticket. Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (Profile), a Software-as-a-Service (“SaaS”) technology company, is laser focused on that business-to-business (“B2B”) market, developing and licensing unique digital content for the iGaming market. Other companies jockeying for the end user, curating gaming and gambling services for consumers (“B2C”) include Bally’s Corporation (NYSE: BALY), DraftKings Inc. (NASDAQ: DKNG), Golden Nugget Online Gaming Inc. (NASDAQ: GNOG) and Penn National Gaming Inc. (NASDAQ: PENN).

Even as the cannabis market continues expanding, pricing for wholesale cannabis has been under protracted pressure from oversupply and price cuts. Make no mistake — the cannabis market is still robust with large upside, and survivors of this supply side shake-out should secure ever-greater market share. The pressures may be most prevalent in California, the world’s biggest cannabis market, as light-deprivation crops reach market in 2021 and the potential for Type 5 cultivation licenses allowing for massive outdoor-growing facilities could be issued in California by 2023. To survive and thrive, companies will need to be nimble, diversify assets across the value chain and generate revenues from multiple venues. That’s preaching to the choir for Los-Angeles-based Cannabis Strategic Ventures Inc. (OTC: NUGS) (Profile). One of California’s publicly traded cannabis cultivators, NUGS has been actively diversifying into integrated operations complete with high-profile retail locations and new indoor grow facilities. NUGS views the shake-out as opportunity and fully expects to capture increased market share as the company continues to diversify.  Throughout the last decade, as the “green rush” has swept across the globe, the wheat has been separated from the chaff, leaving strong companies — such as Canopy Growth (NASDAQ: CGC), Curaleaf Holdings (OTCQX: CURLF), Green Thumb Industries (OTCQX: GTBIF) and Trulieve Cannabis (OTCQX: TCNNF) — still standing as they take necessary steps to secure market share going forward.

Even as the cannabis market continues expanding, pricing for wholesale cannabis has been under protracted pressure from oversupply and price cuts. Make no mistake — the cannabis market is still robust with large upside, and survivors of this supply side shake-out should secure ever-greater market share. The pressures may be most prevalent in California, the world’s biggest cannabis market, as light-deprivation crops reach market in 2021 and the potential for Type 5 cultivation licenses allowing for massive outdoor-growing facilities could be issued in California by 2023. To survive and thrive, companies will need to be nimble, diversify assets across the value chain and generate revenues from multiple venues. That’s preaching to the choir for Los-Angeles-based Cannabis Strategic Ventures Inc. (OTC: NUGS) (Profile). One of California’s publicly traded cannabis cultivators, NUGS has been actively diversifying into integrated operations complete with high-profile retail locations and new indoor grow facilities. NUGS views the shake-out as opportunity and fully expects to capture increased market share as the company continues to diversify.  Throughout the last decade, as the “green rush” has swept across the globe, the wheat has been separated from the chaff, leaving strong companies — such as Canopy Growth (NASDAQ: CGC), Curaleaf Holdings (OTCQX: CURLF), Green Thumb Industries (OTCQX: GTBIF) and Trulieve Cannabis (OTCQX: TCNNF) — still standing as they take necessary steps to secure market share going forward.

The decentralized and global Alien Worlds community, which has become one of the most used decentralized blockchain applications in the world, is pleased to announce that the Alien Worlds Missions game has just launched on the Binance Smart Chain blockchain. Explorers now have the ability to send virtual spaceships on missions throughout the Metaverse, and earn NFTs for use within the game, as well as acquiring NFTs created by various player communities who host frequent events and activities.

To view the full press release, visit https://nnw.fm/LVseC

There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want to kick the habit, there aren’t many smoking-cessation options that have proven safe and effective. Hope may be looming on the horizon, however, with new research building on prior studies that suggest psilocybin is not only a potential solution but also a more effective one. Leading a charge on this front is Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (Profile), a biopharmaceutical firm formed in 2020 for the purpose of developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. Mydecine is part of a renaissance for psychedelic medicine research that is showing real promise in addressing areas of unmet medical need. Those contributing to the resurgence includes peers such as COMPASS Pathways Plc (NASDAQ: CMPS), ATAI Life Sciences N.V. (NASDAQ: ATAI), Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) and Field Trip Health Ltd. (NASDAQ: FTRP).

The decentralized and global Alien Worlds community, which has become one of the most used decentralized blockchain applications in the world, is pleased to announce that the Alien Worlds Missions game has just launched on the Binance Smart Chain blockchain. Explorers now have the ability to send virtual spaceships on missions throughout the Metaverse, and earn NFTs for use within the game, as well as acquiring NFTs created by various player communities who host frequent events and activities.

To view the full press release, visit https://nnw.fm/LVseC

There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want to kick the habit, there aren’t many smoking-cessation options that have proven safe and effective. Hope may be looming on the horizon, however, with new research building on prior studies that suggest psilocybin is not only a potential solution but also a more effective one. Leading a charge on this front is Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (Profile), a biopharmaceutical firm formed in 2020 for the purpose of developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. Mydecine is part of a renaissance for psychedelic medicine research that is showing real promise in addressing areas of unmet medical need. Those contributing to the resurgence includes peers such as COMPASS Pathways Plc (NASDAQ: CMPS), ATAI Life Sciences N.V. (NASDAQ: ATAI), Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) and Field Trip Health Ltd. (NASDAQ: FTRP).

• New ETP, Valour Uniswap, will enable institutions and individuals to invest in Uniswap (UNI) as easily as buying shares from their bank or broker
• Uniswap is the world’s largest decentralized exchange, with US$16.2bn USD in market cap and US$5.1bn USD Total Value Locked (TVL) in the protocol¹
• Valour currently has over US$290m in Assets Under Management (AUM) from its existing products
• Trading in Valour Uniswap to begin on Frankfurt stock exchange later this week

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, today announces that its subsidiary Valour Inc. (“Valour“), an issuer of digital asset exchange traded products (“ETPs“), will launch Valour Uniswap (VALOUR UNISWAP – CH1114178846) on the Börse Frankfurt Zertifikate AG (“Frankfurt“). The Valour Uniswap ETP enables investors to gain exposure to UNI, the native token of the world’s largest decentralised exchange, Uniswap, simply and securely, via their bank or broker.

• New ETP, Valour Uniswap, will enable institutions and individuals to invest in Uniswap (UNI) as easily as buying shares from their bank or broker
• Uniswap is the world’s largest decentralized exchange, with US$16.2bn USD in market cap and US$5.1bn USD Total Value Locked (TVL) in the protocol¹
• Valour currently has over US$290m in Assets Under Management (AUM) from its existing products
• Trading in Valour Uniswap to begin on Frankfurt stock exchange later this week

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, today announces that its subsidiary Valour Inc. (“Valour“), an issuer of digital asset exchange traded products (“ETPs“), will launch Valour Uniswap (VALOUR UNISWAP – CH1114178846) on the Börse Frankfurt Zertifikate AG (“Frankfurt“). The Valour Uniswap ETP enables investors to gain exposure to UNI, the native token of the world’s largest decentralised exchange, Uniswap, simply and securely, via their bank or broker.

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that its wholly owned subsidiary, Valour Inc. (“Valour“), the pioneering issuer of digital asset exchange traded products (“ETPs”), has surpassed US$250 million (equivalent of 2.1 billion Swedish Krona (“SEK”)) in assets under management (“AUM”). This achievement marks an exceptional first ten months of 2021, as AUM increased more than 2560% since the beginning of the year. In the last 30 days, AUM has increased more than US$40m .

To view the full press release, visit https://nnw.fm/qGNKP

DeFi Technologies (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that its wholly owned subsidiary, Valour Inc. (“Valour“), the pioneering issuer of digital asset exchange traded products (“ETPs”), has surpassed US$250 million (equivalent of 2.1 billion Swedish Krona (“SEK”)) in assets under management (“AUM”). This achievement marks an exceptional first ten months of 2021, as AUM increased more than 2560% since the beginning of the year. In the last 30 days, AUM has increased more than US$40m .

To view the full press release, visit https://nnw.fm/qGNKP

As recently as 2015, the retail sales for alkaline waters, those with a pH between 7.0 and 10.0, were less than $95 million. With consumers taking a more proactive approach towards health, alkaline sales are booming. Industry authority Beverage Marketing Corp. forecasts retail sales in the category to balloon to $1.3 billion by 2023, representing 20% of the entire value-added water category. Drivers abound to support the 42.6% compound annual growth rate for the forecast period, which are undergirding exponential growth for The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), the largest independent alkaline water company in the United States. Major grocers, including Walmart Inc. (NYSE: WMT), BJ’s Wholesale Club Holdings Inc. (NYSE: BJ), Costco Wholesale Corporation (NASDAQ: COST) and the Kroger Company (NYSE: KR), have benefited from and are following the category trend, many bottling their own alkaline brands while stocking their shelves and distribution centers to increase options and meet consumer demand.

As recently as 2015, the retail sales for alkaline waters, those with a pH between 7.0 and 10.0, were less than $95 million. With consumers taking a more proactive approach towards health, alkaline sales are booming. Industry authority Beverage Marketing Corp. forecasts retail sales in the category to balloon to $1.3 billion by 2023, representing 20% of the entire value-added water category. Drivers abound to support the 42.6% compound annual growth rate for the forecast period, which are undergirding exponential growth for The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile), the largest independent alkaline water company in the United States. Major grocers, including Walmart Inc. (NYSE: WMT), BJ’s Wholesale Club Holdings Inc. (NYSE: BJ), Costco Wholesale Corporation (NASDAQ: COST) and the Kroger Company (NYSE: KR), have benefited from and are following the category trend, many bottling their own alkaline brands while stocking their shelves and distribution centers to increase options and meet consumer demand.

Today it seems almost unimaginable to wait days or weeks for results from a blood test, but that was the case only a few decades ago. Automated equipment, portable devices and medical innovation have underscored a healthcare evolution that allows for faster diagnoses and subsequent treatment to improve patient outcomes. Innovation remains at the heart of healthcare, keeping up with the times as doctors, patients and insurance companies now expect near-instant results that detect disease at earlier and earlier stages, sometimes even before symptoms present. Early detection and screening have been proven to save lives and billions of dollars, lending to the rise of point-of-care testing (“POCT”), a nascent industry seeing exciting potential. POCT is the wheelhouse for Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) (Profile), whose turnkey POCT-solution-branded HealthTab(TM) delivers real-time results, with the new technology currently being evaluated at leading pharmacies in Canada with North American expansion planned for the future. Harnessing the power of real-world data is an essential piece of the next generation of medical technology as companies such as Abbott Laboratories (NYSE: ABT), Roche Holding AG ADR (OTCQX: RHHBY), IQVIA Holdings Inc. (NYSE: IQV) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) look to remain stewards in helping people live longer, healthier lives.

Today it seems almost unimaginable to wait days or weeks for results from a blood test, but that was the case only a few decades ago. Automated equipment, portable devices and medical innovation have underscored a healthcare evolution that allows for faster diagnoses and subsequent treatment to improve patient outcomes. Innovation remains at the heart of healthcare, keeping up with the times as doctors, patients and insurance companies now expect near-instant results that detect disease at earlier and earlier stages, sometimes even before symptoms present. Early detection and screening have been proven to save lives and billions of dollars, lending to the rise of point-of-care testing (“POCT”), a nascent industry seeing exciting potential. POCT is the wheelhouse for Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) (Profile), whose turnkey POCT-solution-branded HealthTab(TM) delivers real-time results, with the new technology currently being evaluated at leading pharmacies in Canada with North American expansion planned for the future. Harnessing the power of real-world data is an essential piece of the next generation of medical technology as companies such as Abbott Laboratories (NYSE: ABT), Roche Holding AG ADR (OTCQX: RHHBY), IQVIA Holdings Inc. (NYSE: IQV) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) look to remain stewards in helping people live longer, healthier lives.

DeFi Technologies Inc. (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a digital asset investment firm bridging the gap between traditional capital markets and decentralized finance, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers DeFi Technologies’ recent announcement detailing the expansion of its management team.

To hear the audio production, visit: https://www.nnw.fm/BI0rY

To read the original press release, visit: https://nnw.fm/f4w0A

Per the news release, Russell Starr, Executive Chairman of DeFi Technologies, will assume the role of CEO; Diana Biggs, previously CEO of Valour Inc., will be the company’s Chief Strategy Officer; and Johan Wattenstrom, Co-founder and Director of Valour, will serve as the company’s COO.

DeFi Technologies Inc. (NEO: DEFI) (GR: RMJ.F) (OTC: DEFTF), a digital asset investment firm bridging the gap between traditional capital markets and decentralized finance, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers DeFi Technologies’ recent announcement detailing the expansion of its management team.

To hear the audio production, visit: https://www.nnw.fm/BI0rY

To read the original press release, visit: https://nnw.fm/f4w0A

Per the news release, Russell Starr, Executive Chairman of DeFi Technologies, will assume the role of CEO; Diana Biggs, previously CEO of Valour Inc., will be the company’s Chief Strategy Officer; and Johan Wattenstrom, Co-founder and Director of Valour, will serve as the company’s COO.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

To hear the audio production, visit: https://www.nnw.fm/imIah

To read the original press release, visit: https://nnw.fm/QlM2S

“I am extremely pleased with the progress made to-date in this potentially pivotal trial. Our team has been working intensely to open sites in the U.S. and in Europe, understanding where we can best advance this important study,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “With hundreds of potentially competing GBM trials currently enrolling patients, the fact that we've been able to bring these initial sites on-line and get patients enrolled and dosed not only supports our strategic evaluation and selection, but also allows our data demonstrating Berubicin's potential effectiveness to continue to convince the medical community that we have a new drug with impressive potential. With the de-risked profile of Berubicin, its mechanism of action, history of development, encouraging Phase 1 data, and safety in study design, I am personally more optimistic about our work than at any time since joining the company.”

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

To hear the audio production, visit: https://www.nnw.fm/imIah

To read the original press release, visit: https://nnw.fm/QlM2S

“I am extremely pleased with the progress made to-date in this potentially pivotal trial. Our team has been working intensely to open sites in the U.S. and in Europe, understanding where we can best advance this important study,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “With hundreds of potentially competing GBM trials currently enrolling patients, the fact that we've been able to bring these initial sites on-line and get patients enrolled and dosed not only supports our strategic evaluation and selection, but also allows our data demonstrating Berubicin's potential effectiveness to continue to convince the medical community that we have a new drug with impressive potential. With the de-risked profile of Berubicin, its mechanism of action, history of development, encouraging Phase 1 data, and safety in study design, I am personally more optimistic about our work than at any time since joining the company.”